Abstract
Objective: To observe the effect of Shenfu injection (SFI) in treating non small cell lung cancer (NSCLC) patients on quality of life with gemcitabine (GEM) plus cisplatin (GP) regimen.Methods: Thirty-four patients were ready to receive GP regimen chemotherapy for treating NSCLC disease, according to lot-drawing, they were divided into SFI pre-treatment group (18 cases) and SFI post-treatment group (16 cases). SFI pre-treatment group: During the first treatment course, chemotherapy was begun with SFI 60 ml, intravenous dripping on the 3rd day, once daily, consecutively for 10 days; on the 1st day, GP regimen (GEM 1250 mg/m2, intravenous dripping, on the 1st and 8th day; cisplatin 70 mg/m2 on the 2nd day; 21 days as one cycle) was carried out; in the second treatment course GP regimen was merely given to serve as the self-control. SFI post-treatment group: the medicament sequence order was reversed from that of pre-treatment group. Using dual international quality of life (QOL) scores, the effect of SFI on the patients’ QOL was observed through randomized self preand postcrossover control.Results: The QOL in the 34 patients after being treated by SFI in combination with GP chemotherapy regimen in one group, and GP chemotherapy regimen alone in the other, was improved in different degrees, with significant difference (P< 0.01); comparision of SFI combined with GP chemotherapy regimen with GP chemotherapy alone showed that QOL in patients was significantly different (P<0.01).Conclusion: SFI could improve QOL in patients with NSCLC who were treated with GP regimen.
Similar content being viewed by others
References
Felip E, Stahel RA, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). The European Society Med Oncol 2005; 16(1): 28–29.
Ma L, Weng YN, Xiao X. Treatment of NSCLC by traditional medicine and chemotherapy. Chin J Pract Chin Modern Med 2004; 4(1): 709–712.
Ma T, Wu JW. Clinical study on cell immunology and quality of life for chemotherapy combined with Kanglaite in advanced malignant tumor. China J Cancer Prev Treat 2003; 10(11): 1200–1202.
Fayers PM, Aaronson NK, Bjordal K, et al. On behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels: EORTC, 1997: 6.
Schipper H, Clinch J, Mc Murray A, et al. Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 1984; 2(5): 472–483.
Luo J, Sun Y. The research on quality of life in patietns with cancer. Bull Chin Cancer 1995; 4(10): 15.
Liu ZH, Chen RS, Cao Y. effect of Shenfu injection combination with chemotherapy in treating middle or advanced non small cell lung cancer in quality of life. China J Integr Med 2004; 24(9): 856–857.
Aronson NK, Gull A, Keasa S, et al. The European Organization for Research and Treatment of Cancer(EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 1994; 23(2): 75–96.
Wan CH, Cai L, Zhang CZ, et al. Development and evalutaion of Chinese version quality of life scale for lung cancer. Chin J Behav Med Sci 1999; 8(34): 3–5.
Wang JP, Chen ZG, Lin WJ, et al.Assesment of quality of life in cancer patients: EORTC QLQ-C-30 for use in China. Acta Psycholo Sinica 2000; 32(4): 438–442.
Wan CH. Measurement and evaluation of quality of life. 1st ed. Kunming: Yunnan University Publishing Company, 1999: 224–227.
Wan CH, Fang JQ, Zhang CZ, et a. A comparative study on measuring quality of life in patients with liver by FLICscale. Chin J Behav Med Sci 2000; 9 (5): 321–322.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the “999” Shenfu Injection Foundation sponsored by China National Health Ministry and Canadian Terry Fox Foundation for Cancer Research
Rights and permissions
About this article
Cite this article
Wan-yin, W., Shun-qin, L., Hai-bo, Z. et al. Improvement of quality of life with Shenfu injection in non small cell lung cancer patients treated with gemcitabine plus cisplatin regimen. Chin. J. Integr. Med. 12, 50–54 (2006). https://doi.org/10.1007/BF02857431
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02857431